Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer

1 Feb 2018

Abstract excerpt

BRD4 plays a major role in the transcription networks orchestrated by androgen receptor (AR) in castration-resistant prostate cancer (CRPC). Several BET inhibitors (BETi) that displace BRD4 from chromatin are being evaluated in clinical trials for CRPC. Here, we describe mechanisms of acquired resistance to BETi that are amenable to targeted therapies in CRPC. BETi-resistant CRPC cells displayed cross-resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29490263
DOI: 10.1016/j.celrep.2018.02.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerPMID 29490263Read ↗

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Semantic proximity Read ↗

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerSemantic proximity Read ↗

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancerSemantic proximity Read ↗

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read ↗

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.Semantic proximity Read ↗

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancerSemantic proximity Read ↗

Exploiting epigenetic targets to overcome taxane resistance in prostate cancerSemantic proximity Read ↗

Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate CancerSemantic proximity Read ↗

Molecular mechanisms of docetaxel resistance in prostate cancerSemantic proximity Read ↗

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin InteractionsSemantic proximity Read ↗

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.